高级搜索
葛雪珂, 宋玉芝, 甄婵军, 李静, 刘明, 乔学英. 局部进展期食管胃结合部腺癌术前放化疗骨髓受照剂量参数与血液学毒性的关系[J]. 肿瘤防治研究, 2017, 44(12): 804-810. DOI: 10.3971/j.issn.1000-8578.2017.17.0133
引用本文: 葛雪珂, 宋玉芝, 甄婵军, 李静, 刘明, 乔学英. 局部进展期食管胃结合部腺癌术前放化疗骨髓受照剂量参数与血液学毒性的关系[J]. 肿瘤防治研究, 2017, 44(12): 804-810. DOI: 10.3971/j.issn.1000-8578.2017.17.0133
GE Xueke, SONG Yuzhi, ZHEN Chanjun, LI Jing, LIU Ming, QIAO Xueying. Relationship of Irradiated Dosimetric Parameters of Bone Marrow and Hematologic Toxicities in Locally Advanced Adenocarcinoma of Esophagogastric Junction Patients Treated with Preoperative Chemoradiotherapy[J]. Cancer Research on Prevention and Treatment, 2017, 44(12): 804-810. DOI: 10.3971/j.issn.1000-8578.2017.17.0133
Citation: GE Xueke, SONG Yuzhi, ZHEN Chanjun, LI Jing, LIU Ming, QIAO Xueying. Relationship of Irradiated Dosimetric Parameters of Bone Marrow and Hematologic Toxicities in Locally Advanced Adenocarcinoma of Esophagogastric Junction Patients Treated with Preoperative Chemoradiotherapy[J]. Cancer Research on Prevention and Treatment, 2017, 44(12): 804-810. DOI: 10.3971/j.issn.1000-8578.2017.17.0133

局部进展期食管胃结合部腺癌术前放化疗骨髓受照剂量参数与血液学毒性的关系

Relationship of Irradiated Dosimetric Parameters of Bone Marrow and Hematologic Toxicities in Locally Advanced Adenocarcinoma of Esophagogastric Junction Patients Treated with Preoperative Chemoradiotherapy

  • 摘要:
    目的 研究局部进展期食管胃结合部腺癌术前同期放化疗骨髓受照剂量参数与血液学毒性的关系。
    方法 回顾性分析了2013年12月至2016年5月于河北医科大学第四医院行术前同期放化疗的60例局部进展期食管胃结合部腺癌患者的临床资料,评价受照骨髓剂量参数与血液毒性发生的关系。
    结果 全组60例患者中发生2级以上急性血液毒性、中性粒细胞降低、血红蛋白降低和血小板降低分别有33例(55%)、7例(11.67%)、1例(1.67%)和20例(33.33%)。单因素Logistic回归分析显示肋骨V30(P=0.034)、V35(P=0.008)、V40(P=0.018)、V45(P=0.016)、总受照骨髓V25(P=0.026)会增加2级以上白细胞降低的发生率;胸骨V30(P=0.033)增加2级以上血小板降低的发生率;胸骨V20(P=0.041)、V25(P=0.019)、V35(P=0.034)、总受照骨髓V25(P=0.035)增加2级以上急性血液学毒性的发生率。多因素Logistic回归分析显示总受照骨髓V25和肋骨V35是影响2级以上白细胞降低发生率的危险因素,总受照骨髓V25是影响2级以上急性血液学毒性发生率的危险因素。
    结论 对于行术前同期放化疗的局部进展期食管胃结合部腺癌患者,降低骨髓受照剂量可减少2级以上血液学毒性的发生率。

     

    Abstract:
    Objective To identify the relationships between irradiated dosimetric parameters of bone marrow (BM) and hematologic toxicities in locally advanced adenocarcinoma of the esophagogastric junction (AEG) patients treated with preoperative chemoradiotherapy (CRT).
    Methods We retrospectively analyzed the clinical data of 60 AEG patients treated with concurrent oxaliplatin-capecitabine and radiotherapy in the Fourth Hospital of Hebei Medical University from Dec. 2013 to May 2016. The relationship between irradiated dosimetric parameters of bone marrow (BM) and hematologic toxicity (HT) was evaluated.
    Results Among 60 patients with AEG, 55% (33/60) developed grade ≥2 acute HT, 11.67% (7/60) developed neutropenia, 1.67% (1/60) developed anemia and 33.33% (20/60) developed thrombocytopenia. Univariate Logistic regression analysis showed that ribs V30 (P=0.034), ribsV35 (P=0.008), ribsV40 (P=0.018), ribsV45 (P=0.016) and BM-T V25 (P=0.026) were associated with increased risk of grade ≥2 leukopenia; ribsV30(P=0.033) was associated with increased risk of grade ≥2 thrombocytopenia; sternumV20 (P=0.041), sternumV25 (P=0.019), sternumV35 (P=0.034) and BM-T V25 (P=0.035) were associated with increased risk of grade ≥2 HT. Multivariate Logistic regression analysis demonstrated that ribsV35 and BM-T V25 were associated with increased risk of grade ≥2 leukopenia, and BM-T V25 was associated with increased risk of grade ≥2 HT.
    Conclusion Reducing the irradiated dosage of bone marrow may decrease the risk of grade ≥2 hematologic toxicity in locally advanced adenocarcinoma of the esophagogastric junction patients treated with preoperative concurrent chemoradiotherapy.

     

/

返回文章
返回